NRG-BR007

Open to Accrual

Return to Protocol Table

A Phase III Clinical Trial evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less than or Equal to 18: The DEBRA Trial

Principal Investigator

Julia White, MD

Status

Open to Accrual

Date Opened To Accrual

June 07 2021

Disease Site

Breast [BR]

Breast

Phase

III

Developmental Therapeutics

Primary Objective

To evaluate whether breast conservation surgery and endocrine therapy results in anon-inferior rate of ipsilateral-breast tumor recurrence (IBTR) compared tobreast conservation with breast radiation and endocrine therapy.

Patient Population

Target Accrual

1670

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Other

BR007 Request for Supplies from NRG Biobank PGH

BR007 Overview Webinar

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.